Prospect Financial Group LLC Acquires New Holdings in Johnson & Johnson (NYSE:JNJ)

Prospect Financial Group LLC bought a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 2,830 shares of the company's stock, valued at approximately $409,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new position in Johnson & Johnson in the 4th quarter valued at about $1,339,878,000. Janus Henderson Group PLC lifted its stake in shares of Johnson & Johnson by 228.1% during the third quarter. Janus Henderson Group PLC now owns 3,389,361 shares of the company's stock valued at $549,223,000 after buying an additional 2,356,359 shares during the period. Vanguard Group Inc. boosted its position in Johnson & Johnson by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 232,792,559 shares of the company's stock worth $33,666,460,000 after acquiring an additional 1,772,706 shares during the last quarter. Franklin Resources Inc. grew its stake in Johnson & Johnson by 11.4% in the 3rd quarter. Franklin Resources Inc. now owns 16,840,069 shares of the company's stock worth $2,721,355,000 after acquiring an additional 1,729,281 shares during the period. Finally, Amundi raised its holdings in Johnson & Johnson by 16.2% in the 4th quarter. Amundi now owns 11,930,183 shares of the company's stock valued at $1,698,984,000 after acquiring an additional 1,660,458 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company's stock, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the firm's stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the sale, the vice president now owns 21,001 shares in the company, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Remove Ads

Johnson & Johnson Stock Down 1.3 %

Shares of Johnson & Johnson stock traded down $2.15 on Tuesday, hitting $161.14. 7,455,754 shares of the company's stock traded hands, compared to its average volume of 7,086,516. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43. The firm's 50-day moving average is $157.37 and its 200 day moving average is $156.16. The stock has a market cap of $388.32 billion, a P/E ratio of 24.23, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same quarter in the prior year, the firm posted $2.29 earnings per share. Johnson & Johnson's revenue for the quarter was up 5.3% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were issued a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.08%. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.

Analyst Upgrades and Downgrades

JNJ has been the topic of several analyst reports. Leerink Partners decreased their price objective on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a report on Thursday, January 23rd. Argus raised Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Stifel Nicolaus dropped their price objective on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research note on Thursday, January 23rd. Morgan Stanley decreased their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an "equal weight" rating on the stock in a research report on Thursday, January 23rd. Finally, StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, January 25th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $171.33.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.